Neuroimaging Core

ISAVRAD U19提出了一种五个部位、两组（患者和对照）、纵向（3次评估/受试者） 这项研究招募了4,300人。所有5家入组研究中心在招募基因同质性研究方面经验丰富 同伙各种类型的试点数据在各个项目和核心中提供。参与者将是男性 和女性（约50：50比例），年龄> 60岁，有聚合酶链反应史 (PCR)检测出COVID-19感染阳性（75%的样本）或没有COVID-19病史（25%的样本）。 将在入组、18个月和36个月时进行评价。评价将包括 标准化数据采集组合，包括临床状态评估和基于液体的血清采样 生物标志物和遗传学。将在入组时和18个月时进行神经影像学检查。数据采集， 预处理、存档和共享--无论是在U19内部还是与广大科学界--将是 由U19的行政、临床、神经影像和数据管理与统计核心监督。 神经影像核心将管理神经影像采集（2次评估/受试者）、质量控制， 在所有五个研究中心进行数据统一、数据存档和数据共享。图像采集、质量控制和 协调战略将仿效ADNI 3和Mark VCID的战略，并辅以团队专业知识。最小 数据预处理将使用基于体积和基于表面的流水线方法。表面分析 将通过荟萃分析（ENIGMA）协议模拟增强神经成像遗传学， 预计将出现其他关于COVID-19急性后后遗症（PASC）的大型研究， ENIGMA社区将接受正在进行的数据探索的挑战，包括元分析和大型数据分析。 分析。 目标1：图像采集、协调和质量控制。结构MRI和功能MRI图像将 在所有五个研究中心获得。结构MRI采集将模仿ADNI 3、UKBioBank、Lifespan HCP、MarkVCID和GOBS。功能性MRI采集将模仿最新的GOBS。神经影像学核心 将协调各地点的采购，包括协调和质量控制。 目标2：图像预处理和管道分析。Neuroimaging Core将执行采集后质量 控制、图像预处理（伪影去除、运动校正等），并运行广泛使用的体积和 地面管线分析。基于血氧水平依赖性（BOLD）的神经元功能障碍指数 将与葡萄糖代谢和血流交叉验证。 目标3：镜像管理、访问控制和共享。经过防腐处理的原材料和加工过的体积和表面- 基于图像和图像衍生数据（感兴趣区域[ROI]值）和视觉检查分数将 在XNAT系统中存档。将向数据管理部门提供与图纸兼容的数据， 统计核心。

The ISAVRAD U19 proposes a five-site, two-arm (patients and controls), longitudinal (3 assessments/subject) study enrolling 4,300 individuals. All 5 enrollment sites are experienced in recruiting genetically homogenous cohorts. Pilot data of various types are provided in the respective projects and cores. Participants will be men and women (~50:50 ratio) who are > 60 years of age and either have a history of polymerase chain reaction (PCR) test positive COVID-19 infection (75% of sample) or have no history of COVID-19 (25% of sample). Evaluations will be performed upon enrollment, 18 months, and 36 months. Evaluations will comprise a standardized data acquisition battery including assessment of clinical status and serum sampling for fluid-based biomarkers and genetics. Neuroimaging will be conducted at enrollment and at 18 months. Data acquisition, preprocessing, archiving and sharing – both within the U19 and with the scientific community at large – will be overseen by the Administrative, Clinical, Neuroimaging, and Data Management & Statistics Cores of the U19. The Neuroimaging Core will manage neuroimaging acquisition (2 assessments/subject), quality control, harmonization, data archiving and data sharing at all five study sites. Image acquisition, quality control and harmonization strategies will emulate those of ADNI3 and Mark VCID supplemented by team expertise. Minimal data preprocessing will use pipelined approaches both volumetric and surface-based. Surface-based analyses will emulate Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) protocols, with the expectation that other large studies of the post-acute sequelae of COVID-19 (PASC) will emerge and that ENIGMA community will embrace the challenge of ongoing data exploration both meta-analytic and mega- analytic. Aim 1: Image Acquisition, Harmonization and Quality Control. Structural MRI and functional MRI images will be acquired at all five study sites. Structural MRI acquisitions will emulate those of ADNI3, UKBioBank, Lifespan HCP, MarkVCID and GOBS. Functional MRI acquisitions will emulate the latest GOBS. The Neuroimaging Core will coordinate acquisition across sites, including harmonization and quality control. Aim 2: Image Preprocessing and Pipeline analytics. The Neuroimaging Core will perform post-acquisition quality control, image preprocessing (artifact removal, motion correction, etc.), and run widely used volumetric and surface-based pipeline analyses. Blood-oxygen-level-dependent (BOLD)-based indices of neuronal dysfunction will be cross validated with glucose metabolism and blood flow. Aim 3: Image Archiving, Access Control, and Sharing. Anonymized raw and processed volumetric and surfaced- based images and image-derived data (region of interest [ROI] values) and visual-inspection scores will be archived in the XNAT system. Spreadsheet-compatible data will be provided to the Data Management and Statistics Core.